Clinical Pipeline
A comprehensive overview of our 2024–2027 drug development portfolio across oncology, immunology, and rare diseases.
Portfolio Dashboard
23 Active Programs Across 4 Therapeutic Areas
Updated December 1, 2024. Next review scheduled for January 15, 2025.
Phase I
8 compounds
Phase II
9 compounds
Phase III
6 compounds
Total Investment
€1.2 billion
Oncology
11
Active programs targeting solid tumors and hematological malignancies
Immunology
7
Autoimmune and inflammatory disease treatments in development
Rare Diseases
5
Orphan drug designations across metabolic and genetic disorders
Lead Compound: PH-7291
| Parameter | Value | Benchmark | Status |
|---|---|---|---|
| Mechanism of Action | Selective CDK4/6 inhibitor | — | Validated |
| Target Indication | HR+/HER2- metastatic breast cancer | — | Approved |
| Half-life (t½) | 28.4 hours | 24–36 hours | ✓ Within range |
| Bioavailability | 67.3% | >50% | ✓ Exceeds target |
| Phase III Enrollment | 1,247 / 1,500 patients | 100% | 83% complete |
| Projected NDA Filing | Q3 2025 | — | On track |
Trial Sites by Region
- North America: 47 sites across the United States and Canada
- Europe: 38 sites in Germany, France, Spain, Italy, and Poland
- Asia-Pacific: 29 sites in Japan, South Korea, Australia, and Taiwan
- Latin America: 12 sites in Brazil, Argentina, and Mexico
Key Milestones
- March 2022 — Phase I completed (n=84)
- November 2022 — Fast Track designation granted by FDA
- June 2023 — Phase II results published in The Lancet Oncology
- September 2023 — Phase III initiated across 126 sites
- December 2024 — Interim analysis (expected)
“PH-7291 represents a potential best-in-class therapy with a differentiated safety profile. The Phase II overall response rate of 58.3% exceeded our expectations.”
— Dr. Markus Brenner, Chief Medical Officer, speaking at the European Society for Medical Oncology Congress, October 2024
Global Manufacturing Network
Our production facilities operate 24/7 across three continents, ensuring uninterrupted supply to patients in over 90 countries.
Frankfurt, Germany
45,000 m²
Small molecules & solid oral dosage forms. Capacity: 3.2 billion tablets/year. Established 1978.
Boston, USA
28,000 m²
Biologics & cell therapy manufacturing. Capacity: 120,000 L bioreactor volume. Opened 2019.
Singapore
18,500 m²
Sterile injectables & lyophilized products. Capacity: 85 million vials/year. Operational since 2021.
2024 Financial Highlights
Revenue
€8.7B
↑ 12.4% vs. 2023
R&D Investment
€1.9B
21.8% of revenue
Employees
14,320
Across 42 countries
Patents Filed
247
New applications in 2024
Upcoming Investor Events
| January 8–11, 2025 | J.P. Morgan Healthcare Conference | San Francisco, USA |
| February 19, 2025 | Q4 2024 Earnings Call | Virtual |
| March 12–14, 2025 | Cowen Annual Health Care Conference | Boston, USA |
| May 22, 2025 | Annual General Meeting | Frankfurt, Germany |
Contact Our Team
Have questions about our clinical programs, partnership opportunities, or investor relations? Our global team is ready to assist you.
Media Inquiries
press@market-demo.com
+49 69 123 4567
Business Development
partnerships@market-demo.com
+1 617 555 0199
Investor Relations
investors@market-demo.com
+49 69 123 4589